Skip to main content
The Markets by Proactive
Go to Proactive UK
Proactive UK has moved. Proactive’s coverage of London’s small caps continues on proactiveinvestors.com Go there →
Advertisement
The Markets
by Proactive
Proactive UK has moved.
Coverage of London’s small caps continues on proactiveinvestors.com
Go to Proactive UK
The Markets
by Proactive
Proactive UK has moved.
Small-cap coverage continues on .com
Go to Proactive UK
Advertisement
The Markets
by Proactive
Proactive UK has moved.
Small-cap coverage continues on .com
Go to Proactive UK

Archive

Will Vodafone’s third quarter disappoint?

Vodafone, Astrazeneca and Vedanta are among the blue-chips due to report on Thursday.

Commentary around Thursday’s third quarter trading update from Vodafone Plc (LON:VOD) may well focus on possible corporate dealings in India.

In terms of financials, Deutsche Bank anticipates Vodafone will report €13.6bn of group revenue, with €12.3bn coming from services.

“Slowing headline group organic revenue growth in Q3 is hardly a positive catalyst and growth is likely to slow further in Q4 due to German MTR cuts and the leap year comparator,” Deutsche Bank analyst Robert Grindle said in a recent note.

Nonetheless, Deutsche still sees Vodafone as a ‘buy’ with a 285p price target, which suggests substantial upside to the current price of 193.75p.

Thursday’s agenda

Final Result: AstraZeneca PLC (LON:AZN)

Trading Statement: Vodafone Group PLC (LON:VOD), Vedanta Resources PLC (LON:VED), Cranswick plc (LON:CWK), Compass Group PLC (LON:CPG), Aberdeen Asset Management PLC (LON:ADN)

Advertisement
The Markets
by Proactive
Proactive UK has moved.
Small-cap coverage continues on .com
Go to Proactive UK